This study seeks to ascertain whether treatment with higher doses of PEGASYS (270 µg/week) and ribavirin (1600 mg/day) for the first four weeks achieves the plasma concentrations of the product in the blood needed to reduce the half-life of the virions and accelerate the elimination thereof. This would bring the viral kinetic curves in coinfected patients closer to the model described for mono-infected HCV patients, probably achieving improved rates of response in week 12 (early virological response) and posterior in week 72 (sustained virological response).

Therefore, the patients were randomised to treatment with two different doses, 270 µg and 180 µg of PEGASYS, and 1600 mg and 1000-1200 mg of ribavirin.

Stable status in HIV-1 infection, in the investigator's opinion, in other words, patients that are not expected to progress during the study.

Patients treated with stable anti-retroviral therapy (HAART), which does not include nucleoside analogues, for at least 6 weeks before the baseline assessment

Patients that do not receive HAART therapy

Negative pregnancy test in urine or blood

Exclusion Criteria:

Women currently pregnant or in the lactation period.

Patients whose companion is pregnant.

Therapy with interferon (IFN) or ribavirin at any previous time.

Patients with cirrhosis in the hepatic biopsy.

Documented suspicion by ultrasound of hepatocarcinoma.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00356486